Evolving Access Pathways for Cell & Gene Therapies in Parkinson’s Disease
- Opportunities and challenges in coding, coverage, reimbursement, and policy for cell and gene therapies in a common neurodegenerative disease
- Lessons from existing payment models and priorities to enable sustainable access in the future